InsidersTradesSigma
Track the AntriaBio, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was reported on 11 January 2016 (Cession). Among the most active insiders: Elam Nevan C. Every trade is openly available.
Analysts rate AntriaBio, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
AntriaBio, Inc. is a biopharmaceutical company focused on developing treatments for diabetes and other metabolic diseases. It is listed on NASDAQ under the ticker ABIO.